The management of osteoarthritis symptomatology through nanotechnology: a patent review

Exploring the therapeutic potential and chemical properties of trans-chalcone: a comprehensive review

Aim: Trans-chalcone has emerged as a promising candidate for new therapeutic alternatives, owing to its pharmacological properties and potential in various medical areas. This study aimed to conduct a systematic review of articles, patents and clinical trials on trans-chalcone's applications and biological activities.Areas covered: The review proposed a thorough analysis of studies such as scientific articles, patents and clinical studies related to the topic. The searches were carried out in their respective databases and analyzed through the exclusion steps, until selecting studies that corroborate the importance of the topic. The review consolidated evidence from multiple studies, encompassing in vitro and in vivo methodologies across different conditions like cancer, leishmania, skin protection, inflammation and metabolic diseases.Expert opinion: Patent analysis indicated growing interest from pharmaceutical companies and universities, suggesting diverse applications from chronic diseases to previously challenging conditions. Clinical trials utilizing trans-chalcone revealed insufficient investigation, crucial for obtaining essential pharmacokinetic and pharmacodynamic data. While positive results were noted, the review also identified knowledge gaps and areas needing further exploration. In summary, trans-chalcone holds promise for new therapies, supported by evidence from patents, clinical trials and systematic reviews, driving continued research and development in this field.

Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions

Diabetes mellitus (DM) and osteoarthritis (OA) are prevalent chronic conditions with shared pathophysiological links, including inflammation and metabolic dysregulation. This study investigates the potential impact of insulin, metformin, and GLP-1-based therapies on OA progression. Methods involved a literature review of clinical trials and mechanistic studies exploring the effects of these medications on OA outcomes. Results indicate that insulin, beyond its role in glycemic control, may modulate inflammatory pathways relevant to OA, potentially influencing joint health. Metformin, recognized for its anti-inflammatory properties via AMPK activation, shows promise in mitigating OA progression by preserving cartilage integrity and reducing inflammatory markers. GLP-1-based therapies, known for enhancing insulin secretion and improving metabolic profiles in DM, also exhibit anti-inflammatory effects that may benefit OA by suppressing cytokine-mediated joint inflammation and supporting cartilage repair mechanisms. Conclusions suggest that these medications, while primarily indicated for diabetes management, hold therapeutic potential in OA by targeting common underlying mechanisms. Further clinical trials are warranted to validate these findings and explore optimal therapeutic strategies for managing both DM and OA comorbidities effectively.